75 research outputs found
Absorption enhancing excipients in systemic nasal drug delivery
Intranasal drug delivery is becoming an increasingly important form of drug administration for chronic and chronic-intermittent diseases. Important new applications currently in development include drugs for diabetes, osteoporosis, obesity, certain types of convulsive disorders, migraine
headaches, symptomatic pain relief, nausea, and anxiety, among others. Transmucosal absorption across the nasal mucosa is generally limited to molecules less than 1,000 Da. Systemic delivery of larger molecules requires formulations with a suitable transmucosal absorption enhancer. More than
one hundred potential transmucosal absorption enhancing excipients have been tested to date. Nearly all have failed due to poor effectiveness or unacceptable toxicity to the mucosal tissue. Alkylsaccharides, cyclodextrins, and chitosans have emerged as leading candidates for potential broad clinical applications allowing the development of convenient, patient-friendly, needle free formulations of small molecule drugs, as well as, peptide and protein drugs that can be administered at home, at work, or in other public and private settings outside of the doctorâs office or hospital environment
Perfluoroalkyl substances, sex hormones, and insulin-like growth factor-1 at 6â9 Years of age : a cross-sectional analysis within the C8 health project
Background: Exposure to some perfluoroalkyl substances (PFAS), such as perfluorohexane sulfonate
(PFHxS), perfluorooctanoate (PFOA), perfluorooctane sulfonate (PFOS), and perfluorononanoic acid
(PFNA), may alter levels of sex hormones and insulin-like growth factor-1 (IGF-1) in animals. Human
studies on this topic are scarce and none have been conducted in young children.
Objectives: To investigate the relationship between levels of PFAS and estradiol, total testosterone and
IGF-1 in 2,292 children (aged 6-9 years) from the C8 Health Project living near a chemical plant in the
Mid-Ohio Valley (USA) with local contamination from PFOA.
Methods: Serum samples were collected in 2005-2006 and analyzed for PFAS, sex hormones and
IGF-1. Results from regression models were expressed as the adjusted percentage difference (95% CI)
per sex-specific interquartile range (IQR) increment of each PFAS serum concentration. Analyses by
PFAS quartiles were also conducted.
Results: Median concentrations of PFHxS, PFOA, PFOS, and PFNA were 8, 35, 22, and 1.7 ng/mL in
boys and 7, 30, 21, and 1.7 ng/mL in girls. In boys, PFOA concentrations were significantly associated
with testosterone levels (-4.9% [-8.7, -0.8%]); PFOS with estradiol (-4.0% [-7.7, -0.1%]), testosterone
(-5.8% [-9.4, -2.0%]), and IGF-1 (-5.9% [-8.3, -3.3%]); and PFNA with IGF-1 (-3.5% [-6.0, -1.0%]). In
girls, significant associations were found between PFOS and testosterone (-6.6% [-10.1, -2.8%]) and
IGF-1 (-5.6% [-8.2, -2.9%]); and PFNA and IGF-1 (-3.8% [-6.4, -1.2%]). In both sexes, the magnitudes
of the associations decreased monotonically across quartiles for testosterone and PFOS, and for IGF-1
and both PFOS and PFNA.
Conclusions: To our knowledge, this is the first study suggesting that PFAS are associated with lowe
Amphipathic DNA polymers exhibit antiviral activity against systemic Murine Cytomegalovirus infection
<p>Abstract</p> <p>Background</p> <p>Phosphorothioated oligonucleotides (PS-ONs) have a sequence-independent, broad spectrum antiviral activity as amphipathic polymers (APs) and exhibit potent in vitro antiviral activity against a broad spectrum of herpesviruses: HSV-1, HSV-2, HCMV, VZV, EBV, and HHV-6A/B, and in vivo activity in a murine microbiocide model of genital HSV-2 infection. The activity of these agents against animal cytomegalovirus (CMV) infections in vitro and in vivo was therefore investigated.</p> <p>Results</p> <p>In vitro, a 40 mer degenerate AP (REP 9) inhibited both murine CMV (MCMV) and guinea pig CMV (GPCMV) with an IC<sub>50 </sub>of 0.045 ÎŒM and 0.16 ÎŒM, respectively, and a 40 mer poly C AP (REP 9C) inhibited MCMV with an IC<sub>50 </sub>of 0.05 ÎŒM. Addition of REP 9 to plaque assays during the first two hours of infection inhibited 78% of plaque formation whereas addition of REP 9 after 10 hours of infection did not significantly reduce the number of plaques, indicating that REP 9 antiviral activity against MCMV occurs at early times after infection. In a murine model of CMV infection, systemic treatment for 5 days significantly reduced virus replication in the spleens and livers of infected mice compared to saline-treated control mice. REP 9 and REP 9C were administered intraperitoneally for 5 consecutive days at 10 mg/kg, starting 2 days prior to MCMV infection. Splenomegaly was observed in infected mice treated with REP 9 but not in control mice or in REP 9 treated, uninfected mice, consistent with mild CpG-like activity. When REP 9C (which lacks CpG motifs) was compared to REP 9, it exhibited comparable antiviral activity as REP 9 but was not associated with splenomegaly. This suggests that the direct antiviral activity of APs is the predominant therapeutic mechanism <it>in vivo</it>. Moreover, REP 9C, which is acid stable, was effective when administered orally in combination with known permeation enhancers.</p> <p>Conclusion</p> <p>These studies indicate that APs exhibit potent, well tolerated antiviral activity against CMV infection in vivo and represent a new class of broad spectrum anti-herpetic agents.</p
IL-6 Mediated Degeneration of Forebrain GABAergic Interneurons and Cognitive Impairment in Aged Mice through Activation of Neuronal NADPH Oxidase
BACKGROUND:Multiple studies have shown that plasma levels of the pro-inflammatory cytokine interleukin-6 (IL-6) are elevated in patients with important and prevalent adverse health conditions, including atherosclerosis, diabetes, obesity, obstructive sleep apnea, hypertension, and frailty. Higher plasma levels of IL-6, in turn, increase the risk of many conditions associated with aging including age-related cognitive decline. However, the mechanisms underlying this association between IL-6 and cognitive vulnerability remain unclear. METHODS AND FINDINGS:We investigated the role of IL-6 in brain aging in young (4 mo) and aged (24 mo) wild-type C57BL6 and genetically-matched IL-6(-/-) mice, and determined that IL-6 was necessary and sufficient for increased neuronal expression of the superoxide-producing immune enzyme, NADPH-oxidase, and this was mediated by non-canonical NFkappaB signaling. Furthermore, superoxide production by NADPH-oxidase was directly responsible for age-related loss of parvalbumin (PV)-expressing GABAergic interneurons, neurons essential for normal information processing, encoding, and retrieval in hippocampus and cortex. Targeted deletion of IL-6 or elimination of superoxide by chronic treatment with a superoxide-dismutase mimetic prevented age-related loss of PV-interneurons and reversed age-related cognitive deficits on three standard tests of spatial learning and recall. CONCLUSIONS:Present results indicate that IL-6 mediates age-related loss of critical PV-expressing GABAergic interneurons through increased neuronal NADPH-oxidase-derived superoxide production, and that rescue of these interneurons preserves cognitive performance in aging mice, suggesting that elevated peripheral IL-6 levels may be directly and mechanistically linked to long-lasting cognitive deficits in even normal older individuals. Further, because PV-interneurons are also selectively affected by commonly used anesthetic agents and drugs, our findings imply that IL-6 levels may predict adverse CNS effects in older patients exposed to these compounds through specific derangements in inhibitory interneurons, and that therapies directed at lowering IL-6 may have cognitive benefits clinically
Diet-induced obesity and low testosterone increase neuroinflammation and impair neural function
Muscle strength, physical fitness and well-being in children and adolescents with juvenile idiopathic arthritis and the effect of an exercise programme: a randomized controlled trial
The Effects of Dodecyl Maltoside and Sodium Dodecyl Sulfate Surfactants on the Stability and Aggregation of Recombinant Interferon Beta-1b
- âŠ